ARTICLE SUMMARY:
The public market remained receptive to medtech companies and M&A remained active, although valuations dropped. Looking ahead: IPO activity continues to appear promising if we can just keep the government open.
This year-in-review installment of our quarterly US financing and M&A series confirms the optimism that many in the industry are feeling about the near-term prospects for medtech and diagnostics companies.
